Ureter Injury Clinical Trial
Official title:
An Open-Label, Randomized, Parallel Group Study to Investigate the Influence of Renal Impairment on the Efficacy and Safety of Two Doses of Bludigo™ (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used as an Aid in the Determination of Ureteral Patency
This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Subjects between = 18 and = 85 years old - Subjects who signed a written IRB approved, informed consent form - Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure. - An estimated glomerular filtration rate (eGFR) at baseline will be determined using the Modification of Diet in Renal Disease formula (MDRD) and standardized by using individual's body surface area. Subject's renal function will be defined based on the following criteria: - Normal subjects: eGFR of =90 mL/min - Mild renal impairment: eGFR 60 to 89 mL/min - Moderate renal impairment: eGFR 30 to 59 mL/min - Severe renal impairment: eGFR 15 to 29 mL/min Subjects with normal renal function that are judged to be in good health based on medical history, physical examination, vital signs, and laboratory safety tests performed at the Screening Visit and/or prior to administration of study drug. Patients with renal impairment (mild, moderate, or severe) who have a diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in renal function) renal insufficiency meeting criteria at the Screening Visit Exclusion Criteria: - Subjects with eGFR <15 mL/min or expected need for dialysis in the near future, or having only 1 kidney - Subjects with known severe hypersensitivity reactions to Bludigo™ or other dyes, including contrast dyes - Known history of drug or alcohol abuse within 6 months prior to the time of screening visit - Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g., major systemic diseases) - Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures - Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol - Subjects with life expectancy < 6 months - Requirement for concomitant treatment that could bias primary evaluation. - Subjects who are pregnant or breast-feeding |
Country | Name | City | State |
---|---|---|---|
United States | Albany Medical Center | Albany | New York |
Lead Sponsor | Collaborator |
---|---|
Prove pharm |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Difference between the Bludigo™ high dose vs Bludigo™ low dose in urine jet conspicuity score | An exploratory comparison will be performed to assess the difference between the Bludigo™ high dose vs Bludigo™ low dose in urine jet conspicuity score.
The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows: = No jet observed = Weak jet, little color contrast = Color contrast or significant jet flow = Strong jet flow with good color contrast = Strong jet flow with striking contrast in color |
10 to 15 minutes post study drug administration | |
Other | Impact of renal impairment on renal elimination of Bludigo™ | An exploratory comparison will be performed to assess the impact of renal impairment on renal elimination of Bludigo™. | 12 hours post study drug administration | |
Other | Urinary excretion of Bludigo in patients with and without renal impairment | An exploratory assessments of the amount of Bludigo excreted in urine in patients with and without renal impairment. | 12 hours post study drug administration | |
Primary | Paired sample difference (Bludigo - Saline) in urine jet conspicuity score. | Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:
= No jet observed = Weak jet, little color contrast = Color contrast or significant jet flow = Strong jet flow with good color contrast = Strong jet flow with striking contrast in color Paired sample difference (Bludigo™-Saline) in conspicuity score (PSDCS). PSDCS will be calculated for each ureter (left or right) for each subject from each reviewer. |
10 to 15 minutes post study drug administration | |
Primary | Responders to Bludigo | Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:
= No jet observed = Weak jet, little color contrast = Color contrast or significant jet flow = Strong jet flow with good color contrast = Strong jet flow with striking contrast in color A subject is considered a responder to Bludigo™ if there is >=1 point improvement in the conspicuity score following the Bludigo™- treatment vs the saline treatment and the conspicuity score for the Bludigo™ treatment must be (3, 4, or 5). The responder criteria will be assessed separately for each ureter (left or right) from each reviewer. |
10 to 15 minutes post study drug administration | |
Secondary | Incidence of adverse events and serious adverse events. | Percentage of patients in each treatment group who experience an adverse event post treatment | 30 days post study drug administration | |
Secondary | Changes in clinical safety laboratory values | Proportion of subjects with clinically important changes in clinical safety laboratory tests after treatment | 30 days post study drug administration | |
Secondary | Changes in vital signs post treatment | Proportion of subjects with clinically important changes in vital signs after treatment | 30 days post study drug administration | |
Secondary | Changes in ECG post treatment | Proportion of subjects with clinically important changes in ECGs after treatment | 30 days post study drug administration | |
Secondary | Changes in blood pressure by dose group and Renal Impairment Cohort | Comparison of post treatment changes in blood pressure by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment) | 30 days post study drug administration | |
Secondary | Changes in heart rate by dose group and Renal Impairment Cohort | Comparison of post treatment changes in heart rate by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment) | 30 days post study drug administration | |
Secondary | Changes in pulse oximetry by dose group and Renal Impairment Cohort | Comparison of post treatment changes in pulse oximetry by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment) | 30 days post study drug administration | |
Secondary | Time to visualization | To describe the time to visualization (TTV) of blue color in the ureteral jets flow following Bludigo™ treatment | 10 to 15 minutes post study drug administration | |
Secondary | Physician Satisfaction | To determine physicians' overall satisfaction with the Bludigo™ treatment by assessing the proportion of surgeons who agree using the 5-point Physician Satisfaction Agreement Scale (PSAS) with the statement:
"Compared to the saline treatment, my ability to assess ureter patency was improved after the addition of Bludigo™." = Strongly Agree = Agree = Neither Agree nor Disagree = Disagree = Strongly Disagree A surgeon's evaluation is considered satisfactory if the rating is either a 1 (strongly agree) or 2 (agree). |
10 to 15 minutes post study drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05640115 -
Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
|
Early Phase 1 | |
Recruiting |
NCT06054880 -
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency
|
Phase 4 | |
Completed |
NCT03937505 -
A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy
|
Phase 2 | |
Not yet recruiting |
NCT06448143 -
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients
|
Phase 3 | |
Completed |
NCT05769257 -
A Safety and Feasibility Study of IS-001 Injection in Patients Undergoing Robotic Colorectal Surgery
|
Phase 2 | |
Recruiting |
NCT06278753 -
Comparison of Standard Cystoscopy With Carbon Dioxide Cystoscopy
|
||
Recruiting |
NCT05954767 -
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
|
Phase 3 | |
Completed |
NCT04228445 -
3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
|
Phase 3 | |
Completed |
NCT03387410 -
Ureter Identification With IRDye 800BK
|
Phase 1/Phase 2 |